Ocuphire Stock Analysis

OCUP -  USA Stock  

USD 4.81  0.19  3.80%

The big decline in price over the last few months for Ocuphire Pharmamay encourage insiders to take a closer look at the company as it is trading at a share price of 4.81 on 315,389 in trading volume. The company executives failed to add value to investors and positioning the company supply of money to exploit market volatility in May. However, diversifying your holdings with Ocuphire Pharma or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.19. This high volatility is attributed to the latest market swings and not so good earnings reports for some of the Ocuphire Pharma partners.
Please check Your Equity Center.

Search Stock Analysis 

 
Refresh
The Ocuphire Pharma stock analysis report makes it easy to digest most publicly released information about Ocuphire Pharma and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Ocuphire stock analysis module also helps to analyze the Ocuphire Pharma price relationship with some important fundamental indicators such as market cap and management efficiency.

Ocuphire Stock Analysis Notes

About 19.0% of the company outstanding shares are owned by corporate insiders. The company had not issued any dividends in recent years. Ocuphire Pharma had 1-4 split on the 6th of November 2020. Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of various eye disorders. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan. Ocuphire Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 5 people. To find out more about Ocuphire Pharma contact the company at 248 681 9815 or learn more at http://www.ocuphire.com.

Ocuphire Pharma Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Ocuphire Pharma's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Ocuphire Pharma or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Ocuphire Pharma generates negative expected return over the last 90 days
Ocuphire Pharma has high historical volatility and very poor performance
Ocuphire Pharma has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (24.62 M).
Ocuphire Pharma currently holds about 16.4 M in cash with (6.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.5.
Roughly 19.0% of the company outstanding shares are owned by corporate insiders
Latest headline from www.equities.com: Ocuphire Pharma Inc gains 6.1000 percent for June 07 - Equities.com

Ocuphire Largest EPS Surprises

Earnings surprises can significantly impact Ocuphire Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2015-05-08
2015-03-31-0.03-0.020.0133 
2014-11-12
2014-09-30-0.02-0.010.0150 
2016-03-14
2015-12-31-0.25-0.20.0520 
View All Earnings Estimates

Ocuphire Pharma SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Ocuphire Pharma prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Ocuphire Pharma investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Ocuphire Pharma specific information freely available to individual and institutional investors to make a timely investment decision.
6th of January 2021
Financial Statements and Exhibits. Regulation FD Disclosure
View
30th of December 2020
Financial Statements and Exhibits
View
25th of November 2020
Unregistered Sales of Equity Securities. Entry into a Material Definitive Agreement
View
17th of November 2020
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
16th of November 2020
Unclassified Corporate Event
View
12th of November 2020
Unclassified Corporate Event
View
6th of November 2020
Unclassified Corporate Event. Unclassified Corporate Event. Unclassified Corporate Event. Unclassified Corporate Event. Completion of Acquisition or Disposition of Assets
View
3rd of November 2020
Financial Statements and Exhibits. Other Events. Submission of Matters to a Vote of Security Holders. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View

Ocuphire Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Ocuphire Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Ocuphire Pharma backward and forwards among themselves. Ocuphire Pharma's institutional investor refers to the entity that pools money to purchase Ocuphire Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Altium Capital Management LpCommon Shares397 K2.3 M
Ikarian Capital LlcCommon Shares119.6 K693 K
Renaissance Technologies LlcCommon Shares113.6 K660 K
Norris Perne French LlpCommon Shares78.9 K458 K
Pura Vida Investments LlcCommon Shares57.5 K334 K
Comerica BankCommon Shares30 K143 K
Regency Capital Management IncCommon Shares17 K99 K
Note, although Ocuphire Pharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Ocuphire Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 61.81 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Ocuphire Pharma's market, we take the total number of its shares issued and multiply it by Ocuphire Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (60.79) % which means that it has lost $60.79 on every $100 spent on asset. This is way below average. Ocuphire Pharma management efficiency ratios could be used to measure how well ocuphire pharma manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 17th of June 2021, Ocuphire Pharma holds the risk adjusted performance of (0.06), and Coefficient Of Variation of (950.38). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Ocuphire Pharma, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We are able to break down and analyze data for nineteen technical drivers for Ocuphire Pharma, which can be compared to its competitors. Please check Ocuphire Pharma jensen alpha and downside variance to decide if Ocuphire Pharma is priced some-what accurately, providing market reflects its current price of 4.81 per share. Given that Ocuphire Pharma has jensen alpha of (0.51), we recommend you to check out Ocuphire Pharma's recent market performance to make sure the company can sustain itself at a future point.

Ocuphire Pharma Price Movement Analysis

The output start index for this execution was fourty-nine with a total number of output elements of twelve. The Exponential Moving Average is calculated by weighting recent values of Ocuphire Pharma more heavily than older values. View also all equity analysis or get more info about exponential moving average overlap studies indicator.

Ocuphire Pharma Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ocuphire Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ocuphire Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ocuphire Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Ocuphire Pharma Predictive Daily Indicators

Ocuphire Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Ocuphire Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Ocuphire Pharma Forecast Models

Ocuphire Pharma time-series forecasting models is one of many Ocuphire Pharma's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Ocuphire Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Ocuphire Pharma Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Ocuphire Pharma stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Ocuphire shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Ocuphire Pharma. By using and applying Ocuphire Stock analysis, traders can create a robust methodology for identifying Ocuphire entry and exit points for their positions.
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of various eye disorders. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan. Ocuphire Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 5 people.

Current Ocuphire Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Ocuphire analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Ocuphire analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
15.0Strong Buy1Odds
Ocuphire Pharma current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Ocuphire analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Ocuphire stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Ocuphire Pharma, talking to its executives and customers, or listening to Ocuphire conference calls.
Ocuphire Analyst Advice Details

Ocuphire Stock Analysis Indicators

Ocuphire Pharma stock analysis indicators help investors evaluate how Ocuphire Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Ocuphire Pharma shares will generate the highest return on investment. By understating and applying Ocuphire Pharma stock analysis, traders can identify Ocuphire Pharma position entry and exit signals to maximize returns.
Quick Ratio5.15
Fifty Two Week Low3.68
Shares Short Prior Month7.08k
Average Daily Volume Last 10 Day451.16k
Average Daily Volume In Three Month542.24k
Shares Percent Shares Out2.84%
Short Percent Of Float3.25%
Forward Price Earnings-3.97
Float Shares4.59M
Fifty Two Week High14.80
Enterprise Value To Ebitda-3.88
Fifty Day Average4.79
Two Hundred Day Average7.13
Please check Your Equity Center. Note that the Ocuphire Pharma information on this page should be used as a complementary analysis to other Ocuphire Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Complementary Tools for Ocuphire Pharma Stock analysis

When running Ocuphire Pharma stock analysis, check to measure Ocuphire Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ocuphire Pharma is operating at the current time. Most of Ocuphire Pharma's stock examination focuses on studying past and present price action to predict the probability of Ocuphire Pharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Ocuphire Pharma's price. Additionally, you may evaluate how the addition of Ocuphire Pharma to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Fund Screener
Find activelly-traded funds from around the world traded on over 30 global exchanges
Go
The market value of Ocuphire Pharma is measured differently than its book value, which is the value of Ocuphire that is recorded on the company's balance sheet. Investors also form their own opinion of Ocuphire Pharma stock's value that differs from its market value or its book value, called intrinsic value, which is Ocuphire Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ocuphire Pharma's market value can be influenced by many factors that don't directly affect Ocuphire Pharma underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ocuphire Pharma's stock value and its price as these two are different measures arrived at by different means. Investors typically determine Ocuphire Pharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ocuphire Pharma's stock price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.